PB-718

**PB-718** is PegBio's investigational, once-weekly, subcutaneous fixed-dose combination of PB-119, a glucagon-like peptide 1 receptor agonist, and PB-722, a glucagon receptor agonist. The dual-peptide regimen is designed to balance GLP-1 receptor-mediated appetite reduction and glycemic effects with glucagon receptor-mediated energy expenditure and hepatic lipid effects. In a completed phase 1b/2a obesity study, PB-718 produced dose-dependent reductions in body weight, metabolic measures, liver fat, and visceral fat, with mainly mild gastrointestinal adverse events. It is being developed for obesity and metabolic dysfunction-associated steatohepatitis. ([diabetesjournals.org](https://diabetesjournals.org/diabetes/article/73/Supplement_1/768-P/156358/768-P-A-Phase-1b-2a-Trial-to-Assess-the-Safety))

Other names

PB-119 + PB-722PB-119/PB-722